Last reviewed · How we verify
Positron Emission Tomography using [11C]diprenorphine — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Positron Emission Tomography using [11C]diprenorphine (Positron Emission Tomography using [11C]diprenorphine) — Centre Hospitalier Universitaire de Saint Etienne.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Positron Emission Tomography using [11C]diprenorphine TARGET | Positron Emission Tomography using [11C]diprenorphine | Centre Hospitalier Universitaire de Saint Etienne | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Positron Emission Tomography using [11C]diprenorphine CI watch — RSS
- Positron Emission Tomography using [11C]diprenorphine CI watch — Atom
- Positron Emission Tomography using [11C]diprenorphine CI watch — JSON
- Positron Emission Tomography using [11C]diprenorphine alone — RSS
Cite this brief
Drug Landscape (2026). Positron Emission Tomography using [11C]diprenorphine — Competitive Intelligence Brief. https://druglandscape.com/ci/positron-emission-tomography-using-11c-diprenorphine. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab